- Home
- PHAT vs JBGS Comparison
PHAT vs JBGS Comparison
Compare PHAT & JBGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PHAT | JBGS |
|---|---|---|
| Founded | 2018 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 894.0M | 1.0B |
| IPO Year | 2019 | 2017 |
Fundamental Metrics
Financial Performance| Metric | PHAT | JBGS |
|---|---|---|
| Price | $12.70 | $15.12 |
| Analyst Decision | Strong Buy | Sell |
| Analyst Count | 6 | 1 |
| Target Price | ★ $19.83 | $15.00 |
| AVG Volume (30 Days) | ★ 969.5K | 641.5K |
| Earning Date | 04-30-2026 | 05-05-2026 |
| Dividend Yield | N/A | ★ 4.62% |
| EPS Growth | ★ 42.72 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $175,110,000.00 | ★ $498,598,000.00 |
| Revenue This Year | $93.04 | N/A |
| Revenue Next Year | $58.91 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 216.93 | N/A |
| 52 Week Low | $2.21 | $13.28 |
| 52 Week High | $18.31 | $24.30 |
Technical Indicators
Market Signals| Indicator | PHAT | JBGS |
|---|---|---|
| Relative Strength Index (RSI) | 65.50 | 54.73 |
| Support Level | $12.31 | $14.09 |
| Resistance Level | $12.88 | $16.01 |
| Average True Range (ATR) | 0.63 | 0.42 |
| MACD | 0.26 | 0.10 |
| Stochastic Oscillator | 84.06 | 77.93 |
Price Performance
Historical ComparisonAbout PHAT Phathom Pharmaceuticals Inc.
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.
About JBGS JBG SMITH Properties
JBG SMITH Properties is a real estate investment trust based in the United States. It owns, operates, invests in, and develops real estate assets concentrated in amenity-rich, metro-served submarkets in and around Washington, DC. In addition, the company also provides fee-based real estate services to legacy funds through its third-party real estate services business. The operating segments of the company are commercial, multifamily, and third-party asset management and real estate services. It generates maximum revenue from the commercial segment.